Skip to main content

FDA is investigating risk of severe hypocalcemia in dialysis patients taking Prolia (denosumab). After an interim safety

Nov 23, 2022 4:12 pm
Social Author Name
Dr. John Cush
Tweet Content
FDA is investigating risk of severe hypocalcemia in dialysis patients taking Prolia (denosumab). After an interim safety data review reports of hypocalcemia w/ advanced CKD. Monitor Ca, use Ca & vit D supplements. Await further FDA information https://t.co/QMOtYs0eBY https://t.co/wzhIg53kCs
Show on Archive Page
On
Display in Search Results
On
PDQ
Off
×